Mahadevan et al. (2019) published the results of their phase I clinical trial where they administered a novel recombinant humanized monoclonal antibody called Samalizumab that blocks CD200 in chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) patients. Here, CD200 is linked to B-cell chronic lymphocytic leukemia.